Archive for month: March 2019

PRESS RELEASE: AdAlta and Excellerate Bioscience collaborate to advance the development of i-body pipeline

Excellerate Bioscience are excited to announce the formation of a collaborative partnership with AdAlta Limited, a leading Australian biotechnology company that utilises its proprietary technology platform to generate i-bodies as novel protein therapeutics to treat disease. Our internationally recognised expertise in G protein coupled receptor (GPCR) molecular pharmacology will be used to profile AdAlta i-body leads to select superior candidates for a target of commercial interest.

Continue Reading